Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Conditions

• Moderate-to-severe Chronic Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Ponesimod — DRUG
  Oral Tablet

Study Details

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Key Dates

Start date

Feb 17, 2026

Status verified

Jun 2026

Primary completion

Aug 31, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

300 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Ponesimod
  Ponesimod

Primary Outcome Measure

Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs) [ Time Frame: Through study completion, approximately 1 year ]

Central Contacts

• Vanda Pharmaceuticals, Inc.
  202-734-3400
  [email protected]

Locations (4)

Find similar trials in Glendale, AZ